Literature DB >> 33761029

Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.

Richard Huan Xu1,2, Dong Dong3,4,5, Nan Luo6, Eliza Lai-Yi Wong1,2, Yushan Wu1,2, Siyue Yu1, Renchi Yang7, Junshuai Liu8, Huiqin Yuan8, Shuyang Zhang9.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the psychometric properties of the EQ-5D-5L and SF-6D, and to compare their performance among patients living with haemophilia in China.
METHODS: A total of 875 Chinese patients completed the EQ-5D-5L, SF-6D, and Haem-A-QoL questionnaires. Construct validity of the EQ-5D-5L and SF-6D dimensions and indices was assessed by testing hypotheses relating these measures to Haem-A-QoL and clinical measures. The Spearman correlation coefficient was used to assess convergent validity, and one-way analysis of variance (F statistic) was used to assess the known-groups validity (discriminatory power). The agreement between EQ-5D-5L and SF-6D indices was assessed using the intraclass correlation coefficient (ICC) and the Bland-Altman plot.
RESULTS: Both the EQ-5D-5L and SF-6D indices showed acceptable ceiling and floor effects. As hypothesised, both EQ-5D-5L and SF-6D were significantly correlated with Haem-A-QoL (both dimensions and overall score). EQ-5D-5L and SF-6D indices as well as EQ-VAS differentiated patients are known to differ in severity of haemophilia, bleeding status, disabling levels, and comorbidity. The F statistics in the known-groups comparisons suggested that the EQ-5D-5L was slightly more discriminative than the SF-6D. ICC (0.41) and Bland-Altman plot confirmed that the agreement between the EQ-5D-5L and SF-6D indices was poor.
CONCLUSION: Both EQ-5D-5L and SF-6D showed satisfactory construct validity in the measurement of the HRQoL among patients with haemophilia. However, the two instruments may not be used interchangeably in this patient population due to their poor agreement and differing discriminatory power.

Entities:  

Keywords:  EQ-5D; Haemophilia; Psychometric property; Quality of life; Rare disease; SF-6D

Year:  2021        PMID: 33761029     DOI: 10.1007/s10198-021-01273-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  26 in total

1.  Guidelines for the management of hemophilia.

Authors:  A Srivastava; A K Brewer; E P Mauser-Bunschoten; N S Key; S Kitchen; A Llinas; C A Ludlam; J N Mahlangu; K Mulder; M C Poon; A Street
Journal:  Haemophilia       Date:  2012-07-06       Impact factor: 4.287

Review 2.  Genetic diagnosis of haemophilia and other inherited bleeding disorders.

Authors:  F Peyvandi; G Jayandharan; M Chandy; A Srivastava; S M Nakaya; M J Johnson; A R Thompson; A Goodeve; I Garagiola; S Lavoretano; M Menegatti; R Palla; M Spreafico; L Tagliabue; R Asselta; S Duga; P M Mannucci
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

3.  Quality Control Process for EQ-5D-5L Valuation Studies.

Authors:  Juan M Ramos-Goñi; Mark Oppe; Bernhard Slaap; Jan J V Busschbach; Elly Stolk
Journal:  Value Health       Date:  2016-12-22       Impact factor: 5.725

4.  EQ-5D Scores for Diabetes-Related Comorbidities.

Authors:  Patrick W Sullivan; Vahram H Ghushchyan
Journal:  Value Health       Date:  2016-07-15       Impact factor: 5.725

Review 5.  The gene therapy journey for hemophilia: are we there yet?

Authors:  Katherine A High
Journal:  Blood       Date:  2012-07-24       Impact factor: 22.113

6.  Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China.

Authors:  Renchi Yang; Man-Chiu Poon; Koon Hung Luke; Yongqiang Zhao; Jing Sun; Xuefeng Wang; Runhui Wu; Lixia Chen; Xinsheng Zhang; Jingsheng Wu
Journal:  Blood Adv       Date:  2019-12-06

7.  Physical functioning in boys with hemophilia in the U.S.

Authors:  Paul E Monahan; Judith R Baker; Brenda Riske; J Michael Soucie
Journal:  Am J Prev Med       Date:  2011-12       Impact factor: 5.043

8.  Cross-cultural adaptation and validation of Haem-A-QoL in Côte d'Ivoire.

Authors:  Catherine Lambert; N'Dogomo Meité; Ibrahima Sanogo; Sébastien Lobet; Sylvia von Mackensen; Cedric Hermans
Journal:  Haemophilia       Date:  2020-05-11       Impact factor: 4.287

9.  Acceptability and Validity of the EQ-5D in Patients Living With Dementia.

Authors:  Bernhard Michalowsky; Feng Xie; Thomas Kohlmann; Johannes Gräske; Markus Wübbeler; Jochen René Thyrian; Wolfgang Hoffmann
Journal:  Value Health       Date:  2020-05-22       Impact factor: 5.725

10.  The impact of severe haemophilia and the presence of target joints on health-related quality-of-life.

Authors:  Jamie O'Hara; Shaun Walsh; Charlotte Camp; Giuseppe Mazza; Liz Carroll; Christina Hoxer; Lars Wilkinson
Journal:  Health Qual Life Outcomes       Date:  2018-05-02       Impact factor: 3.186

View more
  3 in total

1.  Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China.

Authors:  Guizhi Weng; Yanming Hong; Nan Luo; Clara Mukuria; Jie Jiang; Zhihao Yang; Sha Li
Journal:  Eur J Health Econ       Date:  2022-05-10

2.  Treatment Adherence and Health-Related Quality of Life in Patients with Hemophilia in Hong Kong.

Authors:  Yin Ting Cheung; Pok Hong Lam; Henry Hon Wai Lam; Chung-Tin Ma; Alex Wing Kwan Leung; Raymond Siu Ming Wong; Chi Kong Li
Journal:  Int J Environ Res Public Health       Date:  2022-05-26       Impact factor: 4.614

3.  Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.

Authors:  Shitong Xie; Dingyao Wang; Jing Wu; Chunyu Liu; Wenchen Jiang
Journal:  Health Qual Life Outcomes       Date:  2022-06-16       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.